Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffit Hassan

Showing results (101-110 of 150) with videos related to

Pageof 15
Sort By:
Human Pathology|August 17, 2017
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesotheliomaShingo Inaguma, Jerzy Lasota, Zengfeng Wang, et al.
The Journal of Pathology|October 23, 2019
CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasivenessShingo Inaguma, Jerzy Lasota, Piotr Czapiewski, et al.
CVIR Oncology|December 22, 2025
Mapping drug distribution using CT imaging following direct tissue injection in ex vivo liver: informing clinical implementationRobert Morhard, Michal Mauda-Havakuk, Jose F Delgado, et al.
BMC Cancer|May 9, 2015
Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesotheliomaNeetu Kalra, Jingli Zhang, Anish Thomas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 8, 2005
Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion proteinNoriko Sato, Raffit Hassan, Donald B Axworthy, et al.
Annals of the Rheumatic Diseases|September 7, 2018
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1Andrew L Mammen, Arun Rajan, Katherine Pak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2018
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice GuidelineHedy L Kindler, Nofisat Ismaila, Samuel G Armato, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 5, 2022
Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelinXiufen Liu, Masanori Onda, Nathan Watson, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2014
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopesRonit Mazor, Jaime A Eberle, Xiaobo Hu, et al.
Oncotarget|May 3, 2017
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesotheliomaShingo Inaguma, Zengfeng Wang, Jerzy Lasota, et al.
Pageof 15

Showing results (101-110 of 150) with videos related to

Sort By:
Pageof 15
Human Pathology|August 17, 2017
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesotheliomaShingo Inaguma, Jerzy Lasota, Zengfeng Wang, et al.
The Journal of Pathology|October 23, 2019
CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasivenessShingo Inaguma, Jerzy Lasota, Piotr Czapiewski, et al.
CVIR Oncology|December 22, 2025
Mapping drug distribution using CT imaging following direct tissue injection in ex vivo liver: informing clinical implementationRobert Morhard, Michal Mauda-Havakuk, Jose F Delgado, et al.
BMC Cancer|May 9, 2015
Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesotheliomaNeetu Kalra, Jingli Zhang, Anish Thomas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 8, 2005
Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion proteinNoriko Sato, Raffit Hassan, Donald B Axworthy, et al.
Annals of the Rheumatic Diseases|September 7, 2018
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1Andrew L Mammen, Arun Rajan, Katherine Pak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2018
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice GuidelineHedy L Kindler, Nofisat Ismaila, Samuel G Armato, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 5, 2022
Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelinXiufen Liu, Masanori Onda, Nathan Watson, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2014
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopesRonit Mazor, Jaime A Eberle, Xiaobo Hu, et al.
Oncotarget|May 3, 2017
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesotheliomaShingo Inaguma, Zengfeng Wang, Jerzy Lasota, et al.
Pageof 15